Non-Small Cell Lung Cancer (NSCLC) - Pipeline Assessment and Market Forecasts to 2017


#41727

64pages

GlobalData

$ 2000

In Stock


GlobalData, the industry analysis specialist, has released its new report, “Non-Small Cell Lung Cancer (NSCLC) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Non-Small Cell Lung Cancer (NSCLC) therapeutics market. The report identifies the key trends shaping and driving the global NSCLC therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global NSCLC sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimates that the global Non-Small Cell Lung Cancer (NSCLC) therapeutics market was valued at $4.1 billion in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.2% for the next eight years to reach $6.1 billion by 2017. This high growth forecast is primarily attributed to the strong pipeline landscape, population growth and release of new first-in-class drugs with better safety and efficacy profiles. Low treatment seeking, diagnosis and prescription rates and the availability of generics with better efficacy and safety profiles, pose significant challenges for prospective market entrants. 

Scope

The report provides information on the key drivers and challenges of the NSCLC therapeutics market. Its scope includes:

  • Annualized global NSCLC therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Tyrosine kinase inhibitor, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK inhibitors, glutathione S-transferase binders, growth and survival of multiple myeloma (MM) cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, COX-2 inhibitors, Pan Bcl-2 inhibitors and MUC1 tumor-associated antigens.
  • Analysis of the current and future competition in the global NSCLC therapeutics market. Key market players covered are F. Hoffmann-La Roche Ltd/Genentech, Inc., Pfizer Inc., Novartis AG, Sanofi-aventis, Boehringer Ingelheim, Eli Lilly/Imclone Inc and Abraxis BioScience.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the NSCLC therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NSCLC therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global NSCLC therapeutics market landscape? - Identify, understand and capitalize.
Table of Contents

1 Table of contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Non-Small Cell Lung Cancer: Disease Overview 6
2.1 Overview 6
2.1.1 Etiology 6
2.1.2 Symptoms 6
2.2 Diagnosis 6
2.3 Clinical Classification and Treatment 7
2.4 Prognosis 8
2.5 GlobalData Pipeline Report Guidance 9

3 Non-Small Cell Lung Cancer: Market Characterization 10
3.1 Non-Small Cell Lung Cancer Therapeutics Market Size 10
3.2 NSCLC Market Forecast and CAGR 11
3.3 Drivers and Barriers for the NSCLC Market 12
3.3.1 Drivers of the NSCLC Market 12
3.3.2 Barriers for the NSCLC Therapeutics Market 12

4 Opportunity and Unmet Need 13
4.1 Key Takeaway 14

5 NSCLC Market: Competitive Assessment 15
5.1 Overview 15
5.2 Strategic Competitor Assessment 15
5.3 Product Profile for the Major Marketed Products in the NSCLC Market 16
5.3.1 Avastin 16
5.3.2 Taxotere 17
5.3.3 Gemzar 18
5.3.4 Alimta 19
5.3.5 Tarceva 19
5.3.6 Iressa 20
5.4 Key Takeaway 23

6 Non-Small Cell Lung Cancer Therapeutics: Pipeline Assessment 24

6.1 Overview 24
6.2 Strategic Pipeline Assessment 24
6.2.1 Technology Trends Analytic Framework 24
6.3 NSCLC Therapeutics Promising Drugs under Clinical Development 25
6.4 Drugs under Clinical Development 27
6.4.1 Nexavar (sorafenib) 27
6.4.2 Stimuvax 28
6.4.3 Sutent (sunitinib malate) 28
6.4.4 AMG 706 (motesanib) 29
6.4.5 Vargatef (BIBF 1120) 29
6.4.6 BIBW 2992 (Tovok) 30
6.4.7 Aflibercept (VEGF Trap) 30
6.4.8 Erbitux (cetuximab) 31
6.5 Non-Small Cell Lung Cancer Therapeutics Pipeline by Mechanism of Action 32
6.6 Non-Small Cell Lung Cancer Therapeutics Pipeline Pipeline by Clinical Phases of Development 33
6.6.1 NSCLC Therapeutics Phase III Clinical Pipeline 34
6.6.2 NSCLC Therapeutics Phase II Clinical Pipeline 35
6.6.3 NSCLC Therapeutics Phase I Clinical Pipeline 38
6.6.4 NSCLC Therapeutics Preclinical/ Discovery Clinical Pipeline 39
6.7 Key Takeaway 39

7 Non-Small Cell Lung Cancer Therapeutics Market: Implications for Future Market Competition 40

8 NSCLC Market: Future Players in the NSCLC Market 42
8.1 Introduction 42
8.2 F. Hoffmann-La Roche Ltd 42
8.2.1 Overview 42
8.2.2 Business Description 43
8.2.3 Oncology Portfolio 43
8.3 Pfizer Inc. 44
8.3.1 Overview 44
8.3.2 Business Description 44
8.3.3 Oncolgy Portfolio 46
8.4 Novartis AG 47
8.4.1 Overview 47
8.4.2 Business Description 47
8.4.3 Oncology Portfolio 48
8.5 Sanofi-Aventis 49
8.5.1 Overview 49
8.5.2 Business Description 49
8.5.3 Oncology Portfolio 50
8.6 Boehringer Ingelheim GmbH 51
8.6.1 Overview 51
8.6.2 Business Description 51
8.6.3 Oncology Portfolio 52
8.7 Celgene Corpoation 52
8.7.1 Overview 52
8.7.2 Business Description 52
8.7.3 Major Products & Services 53
8.7.4 Oncology Portfolio 54
8.8 Eli Lilly 54
8.8.1 Overview 54
8.8.2 Business Description 55
8.8.3 Oncology Portfolio 55

9 NSCLC Market: Appendix 57
9.1 Definitions 57
9.2 Abbreviations 57
9.3 Research Methodology 59
9.3.1 Coverage 59
9.3.2 Secondary Research 59
9.3.3 Forecasting 60
9.3.4 Primary Research 63
9.3.5 Expert Panels 63
9.4 Contact Us 63
9.5 Disclaimer 63
9.6 Sources 64
Table 1: Clinical Classification and Treatment 7
Table 2: TNM Staging of Lung Cancer and Survival 8
Table 3: NSCLC Therapeutics Market, Global, Revenues ($bn), 2001-2009 10
Table 4: NSCLC Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2017 11
Table 5: Major Marketed Product in the NSCLC Market, 2010 22
Table 6: NSCLC Therapeutics Market, Promising Drugs Under Clinical Development, 2010 25
Table 7: NSCLC Therapeutics Market, Phase III Clinical Pipeline, 2010 34
Table 8: NSCLC Therapeutics Market, Phase II Clinical Pipeline, 2010 35
Table 9: NSCLC Therapeutics Market, Phase I Clinical Pipeline, 2010 38
Table 10: NSCLC Therapeutics Market, Preclinical/Discovery Clinical Pipeline, 2010 39
Table 11: F. Hoffmann-La Roche Ltd, Oncology and NSCLC Pipeline, 2010 43
Table 12: Pfizer Inc, Oncology and NSCLC Pipeline, 2010 46
Table 13: Novartis AG, Oncology and NSCLC Pipeline, 2010 48
Table 14: Sanofi-Aventis, Oncology and NSCLC Pipeline, 2010 50
Table 15: Boehringer Ingelheim GmbH Oncology and NSCLC Pipeline, 2010 52
Table 16: Celgene Corpoation, Oncology Pipeline, 2010 54
Table 17: Eli lilly, Oncology and NSCLC Pipeline, 2010 55
Figure 1: NSCLC Therapeutics Market, Global, Revenue ($bn), 20012009 10
Figure 2: NSCLC Therapeutics Market, Global, Revenue Forecast ($bn), 2009-2017 11
Figure 3: Opportunity and Unmet Need in the NSCLC Market, 2010 13
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in NSCLC, 2010 15
Figure 5: Technology Trends Analytic Framework of the NSCLC Therapeutics Pipeline, 2010 24
Figure 6: Technology Trends Analytic Framework of NSCLC Therapeutics Pipeline, Description, 2010 25
Figure 7: NSCLC Therapeutics Market, Pipeline by Mechanism of Action (%), 2010 32
Figure 8: NSCLC Therapeutics Market, Pipeline by Phase of Clinical Development (%), 2010 33
Figure 9: NSCLC Therapeutics Market, Implications for Future Market Competition in the, 2010 40
Figure 10: NSCLC Therapeutics Market, Clinical Pipeline by Company, 2010 42
Figure 11: GlobalData Market Forecasting Model 62